Brain glycogen phosphorylase cancer antigen
CA 2258564 A1 · Owner: The Ludwig Institute For Cancer Research · Inventors: Brichard, Vincent; Boon-Falleur, Thierry; Gorin, Fredric A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention describes brain glycogen phosphorylase tumor rejection antigen precursors including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a brain glycogen phosphorylase tumor rejection antigen or precursor thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.